Discover
CBIO
Crescent Biopharma, Inc.
16.89
2 x 12.39
2 x 24.97
bid
ask
+
0.12
0.72%
2 @ 07:30 PM
16.84 -0.05 (0.30%)
| Ytd | 42.41% | |
| 1y | 30.53% |
16.15
day range
17.87
8.94
52 week range
26.98
| Open | 16.67 | Prev Close | 16.77 | Low | 16.15 | High | 17.87 | Mkt Cap | 627.41M |
| Vol | 3.12M | Avg Vol | 359.35K | EPS | -0.14 | P/E | N/A | Forward P/E | -17.04 |
| Beta | 1.29 | Short Ratio | 0.19 | Inst. Own | 8.75% | Dividend | 15.94 | Div Yield | 792.92 |
| Ex Div Date | 01-13 | Earning | N/A | 50-d Avg | 17.04 | 200-d Avg | 15.66 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 28.13M | ||
| Research and Development Expense | 19.39M | ||
| Selling, General and Administrative Expense | 8.74M | ||
| Operating Income | -28.13M | ||
| Net Income | -24.84M | ||
| Net Income Common Stock | -24.84M | ||
| Net Income Common Stock (USD) | -24.84M | ||
| Consolidated Income | -24.84M | ||
| Earnings per Basic Share | -0.74 | ||
| Earnings per Basic Share (USD) | -0.74 | ||
| Earnings per Diluted Share | -0.74 | ||
| Earning Before Interest & Taxes (EBIT) | -24.84M | ||
| Earning Before Interest & Taxes (USD) | -24.84M | ||
| Weighted Average Shares | 30.53M | ||
| Weighted Average Shares Diluted | 30.53M | ||
| Balance Sheet | |||
| Cash and Equivalents | 171.70M | ||
| Cash and Equivalents (USD) | 171.70M | ||
| Current Assets | 179.01M | ||
| Property, Plant & Equipment Net | 2.15M | ||
| Total Assets | 182.76M | ||
| Debt Current | 471.00K | ||
| Total Debt | 1.44M | ||
| Current Liabilities | 18.54M | ||
| Debt Non-Current | 966.00K | ||
| Total Liabilities | 19.50M | ||
| Accumulated Retained Earnings (Deficit) | -219.93M | ||
| Shareholders Equity | 163.26M | ||
| Shareholders Equity (USD) | 163.26M | ||
| Assets Non-Current | 3.75M | ||
| Total Debt (USD) | 1.44M | ||
| Deferred Revenue | 3.12M | ||
| Liabilities Non-Current | 966.00K | ||
| Trade and Non-Trade Payables | 2.54M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 167.00K | ||
| Net Cash Flow from Financing | 136.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -17.57M | ||
| Capital Expenditure | -13.00K | ||
| Net Cash Flow - Business Acquisitions and Disposals | 1.77M | ||
| Issuance (Purchase) of Equity Shares | 280.00K | ||
| Net Cash Flow from Investing | 1.76M | ||
| Net Cash Flow from Operations | -19.46M | ||
| Share Based Compensation | 3.97M | ||